Greatest risk for mortality seen with high blood pressure, glucose intolerance, and low high-density lipoprotein cholesterol.

New opioid prescribing was stable for patients with metastatic cancer with pain and declined for those reporting no pain.

Adverse cardiovascular outcomes and mortality risks were higher among patients with type 1 diabetes relative to type 2 ...

(HealthDay News) — In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes, ...

(HealthDay News) — For persons aged 65 years and younger, nonatherothrombotic causes comprise a considerable burden of acute myocardial infarction (MI), according to a study published in the Sept. 23 ...

The rate of death from second primary malignancies has increased among older prostate cancer survivors in the US, data suggest.

Children undergoing kidney transplantation are susceptible to serious complications if exposed to Epstein-Barr virus infection.

The FDA has approved Bosaya and Aukelso, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo for IV administration in the treatment of moderate to severe SLE.

Findings show discomfort primarily exists among gynecologists seeing patients with a history of endometrial or epithelial ovarian cancer.

Low-dose vaginal estrogens, available in various applications such as creams, tablets, inserts, and rings, are the mainstay of GSM treatment.

(HealthDay News) — Progress in cancer research, including approval of 20 new anticancer therapeutics in the past year, is ...